RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0040-1708511
Establishment and Application of Engineered NIH 3T3 Cell Line with Stable Human RAGE Expression
Funding This research work was supported by the National Natural Science Foundation of China (31671388 and 81302825), the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” (2019ZX09201001), and the Shanghai Jiao Tong University Medical–Engineering Joint Project (YG2019QNA50).
Publikationsverlauf
Publikationsdatum:
21. März 2020 (online)
Abstract
Aim NIH3T3 cell line with expression of human receptor for advanced glycation end-products (hRAGE) transduced with lentivirus vectors was used to analyze affinity, biological activity, and/or molecular mechanisms of molecules targeting the hRAGE pathway.
Method The DNA fragment coding for hRAGE gene was integrated into the genome of NIH3T3 cells using lentivirus transduction. Cells expressing hRAGE were selected with puromycin, and the level of hRAGE expression was analyzed by Western blot. To establish a stable cell line, colonies of hRAGE-expressing cells were generated, and the level of RAGE expression in each engineered cell line was analyzed within 20 generations. Flow cytometry assay was used to verify affinity of anti-hRAGE antibody binding to hRAGE on the surface of engineered cells. The engineered NIH3T3 cell line was applied to assess effects of anti-hRAGE blocking antibody on amyloid β-induced cells apoptosis by CCK-8 assay.
Results The engineered NIH3T3 cell line (hRAGE-NIH3T3) could stably express human RAGE. Commercial anti-RAGE polyclonal antibody could recognize and bind to human RAGE on the surface of hRAGE-NIH3T3 but not original NIH3T3 cells. In addition, hRAGE-NIH3T3 was more sensitive to RAGE pathway-dependent stimulation. Our data show that the hRAGE-NIH3T3 cell line established is an excellent tool in the study of RAGE-targeting molecules based on the cellular level, biological function, and RAGE-mediated molecular mechanisms.
-
Reference
- 1 Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGE-mediated cell signaling. Methods Mol Biol 2013; 963: 239-263
- 2 Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011; 36 (12) 625-632
- 3 Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010; 2 (04) 1184-1195
- 4 Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31 (02) 91-97
- 5 Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274 (28) 19919-19924
- 6 Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000; 113 (Pt 4): 611-620
- 7 Yan SD, Chen X, Fu J. , et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382 (6593): 685-691
- 8 Hofmann MA, Drury S, Fu C. , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (07) 889-901
- 9 Ray R, Juranek JK, Rai V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neurosci Biobehav Rev 2016; 62: 48-55
- 10 Deane R, Singh I, Sagare AP. , et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122 (04) 1377-1392
- 11 Li Y, Wu R, Tian Y. , et al. RAGE/NF-κB signaling mediates lipopolysaccharide induced acute lung injury in neonate rat model. Int J Clin Exp Med 2015; 8 (08) 13371-13376
- 12 Liu Y, Liang C, Liu X. , et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010; 208 (01) 34-42
- 13 Yeh CH, Sturgis L, Haidacher J. , et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50 (06) 1495-1504
- 14 Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010; 31 (04) 665-677
- 15 Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8 (01) 49-62
- 16 Tanji N, Markowitz GS, Fu C. , et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11 (09) 1656-1666
- 17 Wendt T, Harja E, Bucciarelli L. , et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185 (01) 70-77
- 18 Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, Flemington EK, Nelson MA. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp Cell Res 2013; 319 (13) 2081-2090
- 19 Tesarova P, Cabinakova M, Mikulova V, Zima T, Kalousova M. RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?. Neoplasma 2015; 62 (03) 353-364
- 20 Xia P, He H, Kristine MS. , et al. Therapeutic effects of recombinant human S100A6 and soluble receptor for advanced glycation end products(sRAGE) on CCl4-induced liver fibrosis in mice. Eur J Pharmacol 2018; 833: 86-93
- 21 Pontén F, Jirström K, Uhlen M. The Human Protein Atlas--a tool for pathology. J Pathol 2008; 216 (04) 387-393
- 22 Shafaghat F, Abbasi-Kenarsari H, Majidi J, Movassaghpour AA, Shanehbandi D, Kazemi T. preparation of proper immunogen by cloning and stable expression of cDNA coding for human hematopoietic stem cell marker CD34 in NIH-3T3 mouse fibroblast cell line. Adv Pharm Bull 2015; 5 (01) 69-75
- 23 Salehi-Lalemarzi H, Shanehbandi D, Shafaghat F. , et al. Cloning and stable expression of cDNA coding for platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) in NIH-3T3 cell line. Adv Pharm Bull 2015; 5 (02) 247-253
- 24 Abbasi-Kenarsari H, Shafaghat F, Baradaran B, Movassaghpour AA, Shanehbandi D, Kazemi T. Cloning and expression of CD19, a human B-cell marker in NIH-3T3 cell line. Avicenna J Med Biotechnol 2015; 7 (01) 39-44
- 25 Weng S, Zhou L, Deng Q. , et al. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells. BMC Gastroenterol 2016; 16: 25
- 26 Hudson BI, Carter AM, Harja E. , et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008; 22 (05) 1572-1580
- 27 Liu Z, O'Rourke J. Expediting antibody discovery with a cell and bead multiplexed competition assay. SLAS Discov 2018; 23 (07) 667-675
- 28 Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev 2017; 122: 2-19
- 29 Kim Y, Mook-Jung I. PRAK mediates Aβ-RAGE driven autophagy pathway. Oncotarget 2017; 8 (04) 5648-5649
- 30 Oczypok EA, Perkins TN, Oury TD. All the “RAGE” in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev 2017; 23: 40-49
- 31 Litwinoff E, Hurtado Del Pozo C, Ramasamy R, Schmidt AM. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin Pharmacol Ther 2015; 98 (02) 135-144
- 32 Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J 2012; 443 (03) 603-618
- 33 Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia 2018; 32 (07) 1529-1541